CJC-1295 and Ipamorelin: Exploring the Research Behind the Growth Hormone Peptide Combination
All content on this page is intended for educational and research purposes only. CJC-1295 and Ipamorelin are not approved by the FDA for human use and are sold exclusively as research compounds.
What Is the CJC-1295 and Ipamorelin Blend and Why Is It the Most Researched GH Stack?
CJC-1295 and Ipamorelin are two synthetic peptides that work on completely different receptors in the pituitary gland. When studied together, they produce a growth hormone pulse significantly larger than either compound achieves alone. That mechanistic synergy is why this combination has become one of the most consistently studied growth hormone secretagogue pairings in peptide research.
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the signal that tells the pituitary to produce and release growth hormone. Ipamorelin is a selective ghrelin receptor agonist, a completely separate pathway that amplifies the pituitary’s response to GHRH and reduces somatostatin, the hormone that acts as a brake on GH release. When both signals fire simultaneously, the result is a larger, more robust GH pulse than either pathway generates on its own.
The combination is sometimes described as CJC-1295 pressing the accelerator while Ipamorelin releases the brake. That analogy captures the dual-pathway rationale accurately, even if it oversimplifies the underlying biology.
Both compounds are classified as research chemicals. Neither is approved by the FDA for human therapeutic use.
CJC-1295: What the Research Shows
CJC-1295 consists of 29 amino acids and is structurally derived from the first 29 amino acids of endogenous GHRH, with four amino acid substitutions that significantly increase its stability and half-life compared to native GHRH. The no-DAC version has a half-life of approximately 30 minutes to 2 hours. The DAC version (with Drug Affinity Complex) binds to serum albumin, extending the half-life to 6 to 8 days.
The foundational human pharmacokinetic study on CJC-1295 was conducted by Teichman and colleagues, published in the Journal of Clinical Endocrinology and Metabolism (PMID: 17018654, DOI: 10.1210/jc.2006-1702). The study enrolled healthy subjects aged 21 to 61 years in two randomized, placebo-controlled, double-blind ascending dose trials. Results demonstrated that subcutaneous CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1 levels. Importantly, the study found that pulsatile GH secretion was preserved during continuous CJC-1295 stimulation rather than being replaced by a flat, constant elevation. This preservation of pulsatility is considered mechanistically significant because the body’s natural GH release pattern is pulsatile, not continuous.
CJC-1295 activates GHRH receptors on somatotroph cells in the anterior pituitary. The downstream signaling involves adenylyl cyclase activation, elevation of intracellular cyclic AMP, and activation of protein kinase A, which enhances GH gene transcription and vesicle exocytosis. CJC-1295 has approximately 4 times greater receptor affinity than native GHRH, based on receptor binding studies published in 2010.
Ipamorelin: What Makes It Different from Other Growth Hormone Secretagogues
Ipamorelin (NNC 26-0161) is a pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, developed by Novo Nordisk in the late 1990s. It is a selective agonist of the growth hormone secretagogue receptor (GHS-R1a), the ghrelin receptor expressed in the pituitary, hypothalamus, and peripheral tissues.
What distinguishes Ipamorelin from earlier growth hormone secretagogues like GHRP-2 and GHRP-6 is its selectivity profile. Earlier GHRPs stimulated GH release effectively but also caused significant elevation of cortisol, prolactin, and ACTH, hormones that confound research outcomes and are undesirable in clinical contexts. Ipamorelin does not.
The landmark study establishing Ipamorelin’s selectivity was published by Raun et al. in the European Journal of Endocrinology in 1998 (PMID: 9849822, DOI: 10.1530/eje.0.1390552). The study found that Ipamorelin produced robust GH release in rats comparable to GHRP-6 in potency and efficacy, but with no significant elevation of cortisol or ACTH even at 200 times the effective GH-releasing dose. That finding established Ipamorelin as the first truly selective growth hormone secretagogue and is the reason it became the preferred GHRP in subsequent research protocols.
Ipamorelin activates GHS-R1a through a signaling pathway distinct from the cAMP pathway used by GHRH receptors. It operates through phospholipase C and intracellular calcium signaling. This pathway distinction is precisely why combining CJC-1295 with Ipamorelin produces synergistic rather than merely additive GH release.
Why Researchers Study the Two Together
The rationale for combining CJC-1295 and Ipamorelin is dual-pathway amplification. CJC-1295 tells somatotroph cells to produce and release GH through the cAMP/PKA pathway. Ipamorelin tells those same cells to release GH through the PLC/IP3/DAG pathway while simultaneously suppressing somatostatin, the inhibitory signal that limits GH output. When both pathways are activated at the same time, the resulting GH pulse is substantially larger than what either compound achieves alone.
This synergy was formally characterized by Yin et al. (2014), whose research highlighted the amplified GH secretion observed when GHRH receptor agonists and ghrelin receptor agonists are co-administered. The study provided mechanistic grounding for what preclinical researchers had been observing empirically in combined protocols.
A 2025 review of injectable peptide therapy published in an orthopedic surgery context documented that CJC-1295 combined with Ipamorelin showed significantly improved maximum tetanic tension in murine models of glucocorticoid-induced muscle loss. The review noted this finding is limited to animal studies and that human orthopedic data are lacking, but acknowledged the mechanistic plausibility given the role of GH signaling in muscle maintenance and repair.
A broader review of GH secretagogues by Sigalos and Pastuszak (2018) examined the available evidence base and concluded that GH secretagogues show promise but require more long-term studies to establish safety and efficacy in human populations. A 2026 review by Mayfield et al. similarly noted limited evidence for clinical use in humans at present.
CJC-1295 No DAC vs CJC-1295 with DAC
This distinction matters for research protocol design and is frequently misunderstood.
CJC-1295 no DAC (also called Modified GRF 1-29 or Mod GRF 1-29) has a half-life of approximately 30 minutes to 2 hours. It produces a discrete GH pulse when administered and is used in research protocols designed to study pulsatile GH release patterns.
CJC-1295 with DAC binds to serum albumin through the Drug Affinity Complex modification, extending the half-life to 6 to 8 days. This produces sustained GH elevation rather than discrete pulses. It is used in research protocols examining longer-term GH axis modulation.
The Alpha Peps CJC/Ipamorelin blend uses CJC-1295 without DAC, which is the more commonly used format in preclinical research examining pulsatile GH secretion patterns.
What the Research Does Not Yet Support
The CJC-1295 and Ipamorelin combination has more published research behind it than many peptide stacks. That research still has important limitations that researchers should work within accurately.
Human clinical trial data is limited. The Teichman CJC-1295 study is the strongest human pharmacokinetic dataset, but it examined CJC-1295 alone. Controlled human trials examining the combination specifically, with meaningful sample sizes and long-term follow-up, do not exist in the published literature as of 2026.
Long-term safety data is absent. The Sigalos and Pastuszak 2018 review specifically flagged the lack of long-term human safety data as a key limitation. Short-term preclinical safety profiles are reassuring but do not substitute for extended human data.
Neither compound is FDA approved. CJC-1295 was listed on the FDA’s Category 2 bulk drug substance list, restricting compounding pharmacy access. Ipamorelin is an unapproved research compound. Both are on the World Anti-Doping Agency prohibited substance list under category S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics.
IGF-1 elevation has implications. Sustained elevation of GH and downstream IGF-1 carries theoretical long-term risks that have not been studied in the context of these peptides specifically. Researchers should be aware of this when designing protocols.
Research Formats Available
For researchers sourcing CJC-1295 and Ipamorelin for laboratory use, the compounds are available individually or as a pre-blended formulation. The pre-blended format simplifies protocol design when studying the combination. Both are available as lyophilized powder requiring reconstitution. Batch-specific Certificate of Analysis documentation and HPLC-verified purity should be confirmed before use.
Alpha Peps supplies research-grade CJC-1295 and Ipamorelin blend (5mg/5mg) with third-party COA verification. All products are sold exclusively for research purposes and are not intended for human consumption.
Researchers working across related growth hormone axis compounds will also find AOD-9604, MOTS-C, and IGF-1 LR3 in the Alpha Peps catalog.
Frequently Asked Questions
Why are CJC-1295 and Ipamorelin studied together rather than separately?
The two compounds activate completely different receptor pathways in the pituitary. CJC-1295 activates GHRH receptors through the cAMP/PKA signaling cascade. Ipamorelin activates ghrelin receptors through the PLC/calcium signaling cascade. When both pathways are activated simultaneously, the resulting GH pulse is substantially larger than either compound produces alone. This synergistic effect is the primary mechanistic rationale for studying the combination.
What makes Ipamorelin different from GHRP-2 and GHRP-6?
All three are growth hormone secretagogues that activate the ghrelin receptor. The key difference is selectivity. GHRP-2 and GHRP-6 cause significant elevation of cortisol, prolactin, and ACTH alongside GH release. Ipamorelin produces robust GH release with no significant cortisol or ACTH elevation even at very high doses, as established by Raun et al. in 1998 (PMID: 9849822). This clean selectivity profile makes Ipamorelin preferable for research protocols where cortisol confounding is a concern.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 no DAC has a half-life of approximately 30 minutes to 2 hours and produces a discrete GH pulse. CJC-1295 with DAC binds to serum albumin, extending the half-life to 6 to 8 days and producing sustained rather than pulsatile GH elevation. The no-DAC version is more commonly used in research examining pulsatile GH secretion. Alpha Peps supplies the no-DAC format.
Is there human research on CJC-1295 and Ipamorelin?
The strongest human data is the Teichman et al. pharmacokinetic study on CJC-1295 alone (PMID: 17018654), which demonstrated sustained dose-dependent GH and IGF-1 elevation in healthy adults aged 21 to 61. Human data on Ipamorelin alone is limited primarily to the 1998 Raun et al. selectivity study. Controlled human trials on the combination specifically are not published as of 2026.
Are CJC-1295 and Ipamorelin approved for human use?
No. Neither compound is approved by the FDA for human therapeutic use. CJC-1295 has been listed on the FDA’s Category 2 bulk drug substance list. Both compounds are on the WADA prohibited list under category S2. All Alpha Peps products are sold for laboratory research use only and are not intended for human consumption.
Where can I source CJC-1295 and Ipamorelin for research?
Alpha Peps supplies research-grade CJC-1295 and Ipamorelin blend (5mg/5mg) with batch-specific third-party COA verification and documented purity. All products are for laboratory research use only and are not intended for human consumption.
This article is for informational and research purposes only. Nothing on this page constitutes medical advice. CJC-1295 and Ipamorelin are not approved for human use and should only be handled by qualified researchers in appropriate laboratory settings.
